Print（PDF/122KB） Mar. 03, 2020 Corporate
Sumitomo Dainippon Pharma Announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) today announced the following organizational realignment and changes in Executive Officers and other key positions, effective April 1, 2020:
I. Organizational Realignment (effective April 1, 2020)
Corporate Departments
Global Oncology Office is dissolved.
* The functions of business strategy planning and building frameworks for research and development will be transferred to the Global Strategy & Planning function, which will be placed under the Global Head of Oncology, while the functions of formulation/promotion of project strategies and management of research, development, and medical affairs will be transferred to the Oncology Clinical Development Unit.
Corporate Regulatory Compliance & Quality Assurance (Division)
Regulatory Compliance & Quality Assurance Management and Clinical & Research Quality Assurance are integrated and renamed to Regulatory Compliance & Quality Assurance Management.*
* The English name remains unchanged from that of former entities.
Sales & Marketing (Division)
1. Product Management & Promotion Planning is renamed to Product Marketing.
2. CNS Product Management & Promotion Planning is renamed to CNS Product Marketing.
Sumitomo Dainippon Pharma America, Inc. (a holding company in the U.S.)
In order to further enhance the efficiency of North America business, Sumitomo Dainippon Pharma America, Inc. changes its form of incorporation from a holding company to a company that encompasses some of the functions of our North American subsidiaries (Sunovion Pharmaceuticals Inc., Boston Biomedical, Inc., and Tolero Pharmaceuticals, Inc.), including legal affairs, intellectual property, internal audit, compliance, and financial operations.
II. Changes in Executive Officers
(1) Retiring Director (effective March 31, 2020)
Nobuhiko Tamura (currently Member, Board of Directors, Senior Executive Officer)
(2) Promotions (effective April 1, 2020)
Senior Executive Officer
Shigeyuki Nishinaka (currently Executive Officer)
(3) New Executive Officers (effective April 1, 2020)
Koichi Kozuki (currently Executive Director, Drug Development Division)
Isao Shimizu (currently Senior Director, External Innovation)
Yumi Sato (currently Senior Director, Global Corporate Strategy)
(4) Retiring Executive Officers (effective March 31, 2020)
Nobuhiko Tamura (currently Member, Board of Directors, Senior Executive Officer)
Kazuo Koshiya (currently Senior Executive Officer)
Kazuhiro Takada (currently Executive Officer)
* Nobuhiko Tamura will assume the position of Representative Director, President, Nihon Medi-Physics Co., Ltd., effective April 1, 2020.
(5) Changes in the positions assumed by Executive Officers (effective April 1, 2020)
| Position as of April 1, 2020 | Current position | Name |
|---|---|---|
| Member, Board of Directors, Senior Executive Officer Chief Scientific Officer Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Regenerative & Cellular Medicine Manufacturing Plant; Drug Research Division Senior Executive Research Director, Drug Research Division |
Member, Board of Directors, Senior Executive Officer Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Regenerative & Cellular Medicine Manufacturing Plant; Drug Research Division Senior Executive Research Director, Drug Research Division Chief Research Officer |
Toru Kimura |
| Senior Executive Officer Regulatory Affairs; Medical Information, Medical Affairs; Corporate Regulatory Compliance & Quality Assurance Division; Technology Research & Development Division; Manufacturing Division Executive Director, Corporate Regulatory Compliance & Quality Assurance Division Deputy Head of Japan Business Unit |
Senior Executive Officer Technology Research & Development Division; Manufacturing Division Executive Director, Manufacturing Division Deputy Head of Japan Business Unit |
Yoshiharu Ikeda |
| Senior Executive Officer Global Data Design Office; External Affairs; Legal Affairs; Intellectual Property; Corporate Secretariat; IT Management & Digital Transformation; Frontier Business Office |
Senior Executive Officer Global Corporate Strategy; Global Data Design Office; IT Management & Digital Transformation; Frontier Business Office |
Hiroyuki Baba |
| Senior Executive Officer Global Corporate Strategy; Global Business Development; International Business Management |
Executive Officer Global Business Development; International Business Management Senior Director, Global Business Development |
Shigeyuki Nishinaka |
| Executive Officer Corporate Governance; Corporate Communications; Human Resources |
Executive Officer Corporate Communications; Human Resources |
Atsuko Higuchi |
| Executive Officer Chair and CEO, Sumitomo Dainippon Pharma America, Inc. |
Executive Officer Executive Vice President and Chief Corporate Strategy Officer, Sunovion Pharmaceuticals Inc. |
Shinichiro Katayanagi |
| Executive Officer Drug Development Division Executive Director, Drug Development Division Deputy Head of Japan Business Unit |
Executive Director, Drug Development Division | Koichi Kozuki |
| Executive Officer Executive Research Director, Drug Research Division |
Senior Director, External Innovation | Isao Shimizu |
| Executive Officer Executive Vice President and Chief Corporate Strategy Officer, Sunovion Pharmaceuticals Inc. |
Senior Director, Global Corporate Strategy | Yumi Sato |
| Executive Officer CEO, Boston Biomedical, Inc. Global Head of Oncology |
Executive Officer CEO, Boston Biomedical, Inc. |
Patricia S. Andrews |
III. Changes in Personnel (effective April 1, 2020)
| Position as of April 1, 2020 | Current position | Name |
|---|---|---|
| Senior Director, Global Corporate Strategy | Senior Director, Global Oncology Office | Tsutomu Nakagawa |
| Senior Director, Global Business Development | Tolero Pharmaceuticals, Inc. Senior Oncology Business Officer |
Katsumi Tanaka |
| Senior Director, Corporate Secretariat | Senior Director, Pharmacovigilance | Koichi Kino |
| Senior Director, Human Resources | Senior Director, Kyushu Branch | Koji Yamazaki |
| Senior Director, Regenerative & Cellular Medicine Office | External Affairs Senior Director, Corporate Secretariat |
Tomokazu Nagano |
| Senior Director, Regenerative & Cellular Medicine Kobe Center | Senior Research Fellow, iPS Cell-Based Drug Discovery | Atsushi Ikeda |
| Senior Director, DSP Cancer Institute | Senior Director, Research Planning & Coordination | Setsuko Yamamoto |
| Boston Biomedical, Inc. Senior Oncology Strategy Officer |
Boston Biomedical, Inc. Corporate Strategy & Planning Officer for Boston Biomedical, Inc. |
Masashi Murata |
| Position as of April 1, 2020 | Current position | Name |
|---|---|---|
| Senior Director, Regulatory Compliance & Quality Assurance Management | Sunovion Pharmaceuticals Inc. | Teruya Murata |
| Senior Director, Pharmacovigilance | Senior Director, Clinical & Research Quality Assurance | Michie Kuroda |
| Position as of April 1, 2020 | Current position | Name |
|---|---|---|
| Senior Director, Research Planning & Coordination | Senior Director, Regenerative & Cellular Medicine Office Director, Business Planning Group, Regenerative & Cellular Medicine Office |
Atsushi Tsuchida |
| Senior Director, External Innovation | Director, Group Ⅲ, Platform Technology Research Unit Research Planning & Coordination Group, Research Planning & Coordination |
Yukiko Mine |
| Position as of April 1, 2020 | Current position | Name |
|---|---|---|
| Executive Director, Technology Research & Development Division | Deputy Executive Director, Manufacturing Division Senior Director, Suzuka Plant |
Kenji Ueno |
| Position as of April 1, 2020 | Current position | Name |
|---|---|---|
| Senior Director, Product Marketing | Senior Director, Product Management & Promotion Planning | Masayuki Mukai |
| Senior Director, CNS Product Marketing | Senior Director, CNS Product Management & Promotion Planning | Tsuneharu Inoue |
| Senior Director, Personnel Development | Director, Career Development Group, Personnel Development | Satsuki Otani |
| Senior Director, Sapporo Branch | Senior Director, Koshinetsu Branch | Katsuhiko Nishida |
| Senior Director, Tohoku Branch | Senior Director, Sapporo Branch | Manabu Tatsukawa |
| Senior Director, Kita-Kanto Branch | Boston Biomedical, Inc. | Takafumi Shimizu |
| Senior Director, Koshinetsu Branch | Director, Managerial Administration Group, Sales & Marketing Management Director, Planning & Marketing Group, Sales & Marketing Management |
Yasushi Kimura |
| Senior Director, Chiba Branch | Senior Director, Kobe Branch | Noboru Hirata |
| Senior Director, Yokohama Branch | Senior Director, Shikoku Branch | Takafumi Ishibashi |
| Senior Director, Tokai Branch | Senior Director, Kita-Kanto Branch | Hiroshi Takaoka |
| Senior Director, Keiji-Hokuriku Branch | Senior Director, Personnel Development | Junya Kanto |
| Senior Director, Osaka Branch | Senior Director, Human Resources | Ichiro Takahashi |
| Senior Director, Kobe Branch | Director, Labor Relations Group, Human Resources | Tomoko Nakagawa |
| Senior Director, Chugoku Branch | Senior Director, Yokohama Branch | Yasutoshi Araki |
| Senior Director, Shikoku Branch | Director, Product GroupⅠ, Product Management & Promotion Planning | Yoshihiro Ariyama |
| Senior Director, Kyushu Branch | Senior Director, Chugoku Branch | Hidekatsu Kuroda |
| Position as of April 1, 2020 | Current position | Name |
|---|---|---|
| Executive Director, Manufacturing Division Deputy Head of Japan Business Unit |
Executive Director, Technology Research & Development Division | Kazuhiko Takahashi |
| Senior Director, Suzuka Plant | Senior Manufacturing Officer | Hiroyuki Nishii |
| Deputy Senior Director, Administration, Suzuka Plant | Deputy Senior Director, Manufacturing Department Ⅱ, Suzuka Plant | Kazuyuki Fujihara |
| Deputy Senior Director, Manufacturing Department Ⅱ, Suzuka Plant | Director, Formulation Research GroupⅠ, Formulation Research & Development Laboratories | Toru Fukushima |
Inquiries from the Press